Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00717145 · ClinicalTrials.gov registry record · Phase 1

Food Effects on the Relative Bioavailability of Different Dosages of Risedronate

A Phase 1 study, sponsored by Warner Chilcott.

Completed
Registry status
Phase 1
Development phase
94
Enrollment target

NCT00717145 is a Phase 1 study that has completed, run by Warner Chilcott. The registered enrollment target is 94 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00717145, a Phase 1 study, has completed, sponsored by Warner Chilcott.

COMPLETED
Registry status
Phase 1
Development phase
94 participants
Enrollment target

Study Summary

Randomized, open-label, multi-center, 4-treatment, 4-period crossover study. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2, 3, and 4), 4 treatment periods (4 days each), 3 washout periods (14 to 17 days in duration separating each treatment period), and exit procedures.

Interventions

  • DRUG risedronate

Trial Details

FieldValue
Enrollment Target 94 participants
Start Date 2008-07
Est. Completion 2008-09
Phase Phase 1

Sponsor

Warner Chilcott

53 total trials

What the Registry Record Tells You About NCT00717145

The ClinicalTrials.gov registry entry for NCT00717145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which risedronate is the first listed.

NCT00717145 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00717145 about?

NCT00717145 is a clinical study titled "Food Effects on the Relative Bioavailability of Different Dosages of Risedronate". Randomized, open-label, multi-center, 4-treatment, 4-period crossover study. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2, 3, and 4), 4 treatment periods (4 days each), 3 washout periods (14 to 17 days in duration separating each treatment per...

What is the current status of trial NCT00717145?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2008-07. Estimated completion is 2008-09.

What interventions are being tested in trial NCT00717145?

The interventions under investigation include: risedronate (DRUG).

Who is sponsoring clinical trial NCT00717145?

This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.